This is a working overview of peptide purity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-31. Anything still debated is marked as such rather than presented as settled.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
== Toxicity, storage, and deactivation == Cyanogen bromide can be stored under dry conditions at 2 to 8 °C for extended periods. Cyanogen bromide is volatile, and readily absorbed through the skin or gastrointestinal tract. Therefore, toxic exposure may occur by inhalation, physical contact, or ingestion. It is acutely toxic, causing a variety of nonspecific symptoms. Exposure to even small amounts may cause fatal injury. LD50 orally in rats is reported as 25–50 mg/kg. Cyanogen bromide was used as a chemical weapon in the World War I by Austro-Hungarian forces, either as benzene solution or mixture with 25% bromoacetone and 50% benzene. The recommended method to deactivate cyanogen bromide is with sodium hydroxide and bleach. The aqueous alkali hydroxide instantly hydrolyzes BrCN to alkali cyanide and bromide. The cyanide can then be oxidized by sodium or calcium hypochlorite to the less toxic cyanate ion. Deactivation is extremely exothermic and may be explosive.
Some of the Democratic National Committee (DNC) emails leaked to the public in June and July 2016 showed that the committee leadership had favored Clinton over him and had worked to help Clinton win the nomination. On July 12, 2016, Sanders formally endorsed Clinton in her unsuccessful general election campaign against Republican Donald Trump, while urging his supporters to continue the "political revolution" his campaign had begun. Following his endorsement, Sanders spent weeks campaigning for Clinton, holding 39 rallies in 13 states during the final three months before the 2016 election.
=== Pharmacokinetics === Lercanidipine is slowly but completely absorbed from the gut. It has a total bioavailability of 10% due to an extensive first-pass effect, or up to 40% if taken after a fatty meal. Highest blood plasma levels are reached after 1.5 to 3 hours. The substance is quickly distributed into the tissues and bound to lipid membranes, where it forms a depot. The circulating fraction is almost completely (>98%) bound to plasma proteins. It is completely metabolized in the liver, mainly via CYP3A4. Elimination half-life is 8 to 10 hours, and the drug does not accumulate. Because of the depot effect, the antihypertensive action lasts for at least 24 hours. 50% is excreted via the urine.
Beginning in 1979 Lagin has drawn and photographed many hundreds of abstract, symbolic, representational, and schematic sand drawings; all drawn by him on smooth beach sand during early morning low tides using small sticks from plants grown in his garden with seeds collected from wild places he earlier photographed. For him inscribing his 'seeing' in the sand, as part of the earth and the world, expresses the fundamental natural presence of symbols in nature and the 'grounded-ness' of symbolic feeling and meaning." Lagin's drawings, both representational and abstract, include elemental symbols, imaginary creatures and "biomorphic and geomorphic life forms and their spiritual metaphysical ecologies", personal life scenes and maps, and symbols and visual metaphors derived from natural history, geography, geology, mathematics, electricity and electronic circuitry, physics, optics, chemistry, and from his imagination. Lagin's first oil and acrylic paintings on canvas were done between 1967 and 1970. He did no paintings between 1970 and 1982 while doing music, and all of his early physical paintings were either given away or lost in the 1982 flood in Marin County, California. In 1992 Lagin started digital (electronic) painting and drawing while resuming oil and acrylic painting and drawing on canvas, and art and sand papers. His paintings and drawings, with various forms of representation and abstraction, are of nearby seascapes, landscapes, 'desertscapes', 'homescapes', and 'creatures'.
== Life and education == Christian Hackenberger grew up in Damme. He attended the Gymnasium Damme, where he obtained his Abitur in 1995. After completing his civil service, he studied chemistry at the Albert-Ludwigs-Universität in Freiburg (1996–1998) and the University of Wisconsin-Madison (M.S. with Samuel H. Gellman, 1998–1999), with support from the German Academic Scholarship Foundation. He pursued his doctoral studies at the RTWH Aachen (2000–2003), where he worked under Prof. Carsten Bolm as a Kekulé Fellow from the Fonds der Chemischen Industrie. During this time, he also worked as an editorial assistant in scientific journalism for the WDR broadcast "Quarks & Co". From 2003 to 2005 he was a DAAD Postdoctoral Fellow at the Massachusetts Institute of Technology under Prof. Barbara Imperiali. In 2005, Hackenberger founded his own research group at the Free University of Berlin in 2005 as an Emmy Noether Fellow. In 2011, he was appointed as W2 Professor of Bioorganic Chemistry at the Free University of Berlin as the first Plus 3 awardee from the Boehringer Ingelheim Foundation. In 2012, he became Leibniz-Humboldt Professor for Chemical Biology at the Leibniz Research Institute for Molecular Pharmacology and the Humboldt University of Berlin. In 2020, Hackenberger co-founded the Munich-based biotechnology company Tubulis, which specializes in developing antibody-drug conjugates. He has served as associate editor of the Royal Society of Chemistry's scientific journals Organic and Biomolecular Chemistry (2015–2023) and Chemical Science (since 2024).
Sources: en.wikipedia.org
Writer G. Pascal Zachary argues in a Wired essay that legalizing performance-enhancing substances, as well as genetic enhancements once they became available, would satisfy society's need for übermenschen and reverse the decline in public interest in sports. Sports scholar Verner Moller argues that society is hypocritical when it holds athletes to moral standards, but do not conform to those morals themselves. Fox Sports writer Jen Floyd Engel stated in an article, "We live in a pharmacological society. We live in a society of short cuts, of fake this and enhanced that, and somehow we keep trying to sell the line that sports has become this evil empire of cheating. The reality is athletes are merely doing what so many of us do and celebrate and watch every single day of our lives." Sociologist Ellis Cashmore argues that what is considered doping is too arbitrary: transfusing blood cells is not allowed, but other methods of boosting blood cell count, such as hypobaric chambers, are allowed. Other scholars have advanced similar arguments. In 2023, Australian businessman Aron D'Souza announced the Enhanced Games, a sports event permitting doping. British academic Byron Hyde criticized the Games for coercing retired athletes on low salaries into participating with large financial incentives, but observed that many other sports also coerce athletes into harming themselves for fame or money, including the Olympics. He observed that athletes increasingly face an "enhance or retire" dynamic.
== Description == The mushroom species is distinguished by its fruit bodies, pure white when young and sometimes yellowing with age. The cap is about 4–9 centimetres (1+1⁄2–3+1⁄2 in) wide, shaped like a petal or a fan. The stipe is either very short or completely absent, and the flesh has a faint but pleasant smell. The gills are crowded, and decurrent if a stipe is present. The flesh is thin and fragile compared to the oyster mushrooms (Pleurotus ssp.). The spore print is white.
=== Binding assays === Polyhistidine-tagging can be used to detect protein-protein interactions in the same way as a pull-down assay. Polyhistidine tagging has several advantages over other tags commonly used for pull-down assays, including its small size, high binding capacity of the resin, few naturally occurring proteins binding to the carrier matrices and the increased stability of the carrier matrix over monoclonal antibody matrices.
== Defense mechanisms == Many small reptiles, such as snakes and lizards, that live on the ground or in the water are vulnerable to being preyed on by all kinds of carnivorous animals. Thus, avoidance is the most common form of defense in reptiles. At the first sign of danger, most snakes and lizards crawl away into the undergrowth, and turtles and crocodiles will plunge into water and sink out of sight.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.